SCYNEXIS (SCYX) to Release Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. The firm had revenue of $0.98 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Stock Performance

SCYX opened at $1.04 on Tuesday. The company’s 50 day moving average is $1.06 and its 200 day moving average is $1.23. The company has a market cap of $40.54 million, a price-to-earnings ratio of -1.41 and a beta of 1.67. SCYNEXIS has a 12-month low of $0.82 and a 12-month high of $3.07.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Saturday.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.